Antibacterial Activity of the Novel Drug Gepotidacin against Stenotrophomonas maltophilia—An In Vitro and In Vivo Study

Stenotrophomonas maltophilia is increasingly recognized as a nosocomial bacterial pathogen with a multi-drug resistance profile. In this study, the novel drug gepotidacin, the first compound of the novel triazaacenaphthylene topoisomerase inhibitor antibiotics class, was evaluated on its activity ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanders, Maike Isabell, Ali, Eyhab, Buer, Jan, Steinmann, Joerg, Rath, Peter-Michael, Verhasselt, Hedda Luise, Kirchhoff, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868531/
https://www.ncbi.nlm.nih.gov/pubmed/35203795
http://dx.doi.org/10.3390/antibiotics11020192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868531/
https://www.ncbi.nlm.nih.gov/pubmed/35203795
http://dx.doi.org/10.3390/antibiotics11020192

Ejemplares similares